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P-3 Fatty Acids for the Prevention of Atrial
ibrillation After Coronary Artery Bypass Surgery
Randomized, Controlled Trial
eonardo Calò, MD, FESC, Leopoldo Bianconi, MD, Furio Colivicchi, MD, FESC,
ilippo Lamberti, MD, Maria Luisa Loricchio, MD, Ermenegildo de Ruvo, MD, Antonella Meo, MD,
laudio Pandozi, MD, FESC, Mario Staibano, MD, Massimo Santini, MD, FESC, FACC
ome, Italy
OBJECTIVES The aim of this study was to assess the efficacy of preoperative and postoperative treatment
with n-3 polyunsaturated fatty acids (PUFAs) in preventing the occurrence of atrial
fibrillation (AF) after coronary artery bypass graft surgery (CABG).
BACKGROUND Postoperative AF is a common complication of CABG. There is growing clinical evidence
that PUFAs have cardiac antiarrhythmic effects.
METHODS A total of 160 patients were prospectively randomized to a control group (81 patients, 13
female, 64.9  9.1 years) or PUFAs 2 g/day (79 patients, 11 female, 66.2  8.0 years) for at
least 5 days before elective CABG and until the day of discharge from the hospital. The
primary end point was the development of AF in the postoperative period. The secondary end
point was the hospital length of stay after surgery. All end points were independently
adjudicated by two cardiologists blinded to treatment assignment.
RESULTS The clinical and surgical characteristics of the patients in the two groups were similar.
Postoperative AF developed in 27 patients of the control group (33.3%) and in 12 patients of
the PUFA group (15.2%) (p  0.013). There was no significant difference in the incidence
of nonfatal postoperative complications, and postoperative mortality was similar in the
PUFA-treated patients (1.3%) versus controls (2.5%). After CABG, the PUFA patients were
hospitalized for significantly fewer days than controls (7.3  2.1 days vs. 8.2  2.6 days,
p  0.017).
CONCLUSIONS This study first demonstrates that PUFA administration during hospitalization in patients
undergoing CABG substantially reduced the incidence of postoperative AF (54.4%) and was
associated with a shorter hospital stay. (J Am Coll Cardiol 2005;45:1723–8) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.079American College of Cardiology Foundation
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atrial fibrillation (AF) is the most common complication
ssociated with coronary artery bypass graft surgery
CABG) (1). In addition, postoperative AF imparts an
ncreased risk for other major complications after cardiac
urgery, while also prolonging hospital length of stay, and
ncreasing costs (1). Owing to such relevant clinical and
conomic implications, several studies have been undertaken
n order to define effective pharmacological and nonphar-
acological interventions for the prevention of this trouble-
ome arrhythmia (2–4).
Recent experimental and clinical studies have shown that
-3 polyunsaturated fatty acids (PUFAs) may be effective in
reventing cardiac arrhythmias and sudden death (5–25). In
articular, PUFAs have shown significant antiarrhythmic
ffects on the atrial muscle in rat experimental models (24).
urthermore, the human consumption of fish inducing high
lasma PUFA concentration has been associated with a
ower incidence of AF in a 12-year follow-up study (25).
The aim of this study was to assess the efficacy and safety
f preoperative and postoperative treatment with n-3 PUFA
n preventing the occurrence of AF after CABG.
From the Department of Cardiac Diseases, San Filippo Neri Hospital, Rome, Italy.
Manuscript received January 20, 2005; revised manuscript received February 18,
005, accepted February 22, 2005.ETHODS
atients. The study cohort consisted of 160 patients (136
en and 24 women; mean age, 65.6  8.5 years) undergo-
ng CABG. These patients were recruited from consecutive
ubjects referred to our institution from February 2003 to
ugust 2004 for elective cardiac surgery. To be included in
he study, patients needed to be older than 18 years of age,
n normal sinus rhythm, and in stable hemodynamic con-
itions before surgery. Patients were excluded in the follow-
ng cases: need for concomitant valvular surgery; prior
istory of any kind of supraventricular arrhythmias; current
se of antiarrhythmic medications other than beta-receptor
ntagonists, calcium-channel antagonists, or digitalis. All
nrolled patients provided written informed consent to take
art in the investigation.
tudy design. The study was planned as an open-label,
rospective, randomized, controlled trial with parallel
roups. The main goal of the study was to assess the effects
f PUFAs in the prevention of the occurrence of AF after
oronary surgery. The study protocol was approved by the
thics committee of our institution. Also, as currently used
t our institution for investigator-initiated research that is
ot supported by any industrial grant, the ethics committee
lso served as the data safety committee.Eligible patients were assigned to one of the two study
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N-3 Fatty Acids and Postoperative AF May 17, 2005:1723–8rms according to a computer-generated randomization list:
) control group (usual care); and 2) usual care plus PUFAs.
herapy with PUFAs, at the dosage of two capsules/day,
as started immediately after randomization and continued
or at least five days before surgery.
In the absence of evidence for preferred doses of treat-
ents, we decided on the daily doses of n-3 PUFAs as two
elatin capsules containing 850 to 882 mg eicosapentaenoic
cid (EPA) and docosahexaenoic acid (DHA) as ethyl esters
n the average ratio of EPA/DHA 1:2 (8,9). This pharma-
eutical product is commercially available in Italy (Società
rodotti Antibiotici, Milan, Italy) and has already been used
n other trials (8,9).
The administration of PUFAs in the immediate postop-
rative period (24 to 36 h) was done, if needed, through a
asogastric tube. Treatment with PUFAs continued until
ospital discharge. Compliance was monitored by pill count
nd was 98%.
The study was not funded by any pharmaceutical com-
any (except for the provision of PUFAs without costs).
Midline sternotomy procedures with standard surgical
echniques for cardiopulmonary bypass in CABG were
sed. Nineteen patients underwent “off-pump” CABG.
yocardial protection was afforded with cold potassium
ardioplegia.
After surgery patients were admitted to the intensive care
nit and were subsequently transferred to a monitored
ntermediate care unit. In these two settings, continuous
hythm monitoring was performed for the first four to five
ostoperative days. The electrocardiographic data were
tored for 24 h and reviewed on a daily basis by the cardiac
urgery team. The printouts of all abnormal rhythms were
lso reviewed for any episodes of arrhythmia by the attend-
ng cardiologist. All printouts were included in clinical
ecords.
After discharge from the monitored intermediate care
nit to the cardiovascular ward, patients had an electrocar-
iogram daily until hospital discharge. Additionally, an
lectrocardiogram was also recorded in case of symptoms or
hen an arrhythmia was suspected on clinical grounds; AF
pisodes were always treated under the direction of the
ttending cardiologist.
After discharge all patients were asked to report to the
utpatient department of our institution in case of any
Abbreviations and Acronyms
AF  atrial fibrillation
CABG coronary artery bypass graft surgery
CI  confidence interval
DHA  docosahexaenoic acid
EPA  eicosapentaenoic acid
OR  odds ratio
PUFA  n-3 polyunsaturated fatty acidelevant symptom. Additionally, all patients had a follow-up cisit four weeks after discharge, including physical exami-
ation and a 12-lead electrocardiogram.
tudy end points. The primary end point of the study was
he development of postoperative AF as detected by elec-
rocardiography during the hospitalization period. Postop-
rative AF was defined as any electrocardiographically
onfirmed episode of AF for 5 min in duration or
equiring intervention for angina or hemodynamic compro-
ise. After an episode of AF or at hospital discharge, formal
tudy participation ended, and the patient was withdrawn
rom any further analysis.
The secondary end point was the hospital length of stay
fter surgery. All end points were independently adjudicated
fter discharge by two cardiologists, blinded to treatment
ssignment, on the basis of clinical records and electrocar-
iographic tracings.
tatistical analysis. The primary analysis of all outcomes
as by intention-to-treat. The occurrence of postoperative
F in the two treatment groups was tested with the odds
atio (OR) of the two-binomial proportion analysis.
The cumulative risk of occurrence of AF within each
roup was estimated by means of the Kaplan-Meier
ethod. The survival curves of the two different treatment
roups were then formally compared by use of the log-rank
est.
Mean ( SD) were calculated for continuous variables,
nd frequencies were measured for categorical variables.
ifferences between groups were analyzed by an unpaired
tudent t test for continuous variables, while, in case of
ategorical variables, group differences were examined by
hi-square or Fisher exact tests as appropriate. In particular,
he Fisher exact tests was applied in case of an expected
requency of 5. A value of p  0.05 was considered
ignificant.
Sample size calculation was based on an expected 35%
ccurrence of postoperative AF in the control group and on
n expected 20% occurrence of AF in the PUFA arm.
onsequently, with a significance level of 0.05 and a test
ower of 0.80, the resulting sample size was 138 patients in
ach treatment group.
A stepwise logistic regression analysis was performed to
elect the predictors of AF after surgery. The model was
uilt using variables that demonstrated a p value 0.10 in
nivariate analysis. The significance within the model was
valuated with the Wald statistical test. All tests were
wo-tailed and performed by SPSS 11.5 statistic software
Chicago, Illinois). According to the study protocol, an
nterim analysis of safety and efficacy was planned every six
onths during the study.
ESULTS
nrollment was started in February 2003, and the third
ormal interim analysis was performed on August 30,
004. By that time, 160 patients had been enrolled, and
omplete data were available for all patients. The interim
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May 17, 2005:1723–8 N-3 Fatty Acids and Postoperative AFnalysis showed a significant effect in favor of the PUFA
roup compared with controls (p  0.013). Conse-
uently, in accordance with the ethics committee of our
nstitution, a decision was made to terminate enrollment.
he study results were then reported as of September 12,
004.
Of the 160 patients enrolled in the study, 81 were
ssigned by randomization to the control group and 79 to
he PUFA group. The two groups were similar with regard to
ll clinical and surgical characteristics, as shown in Table 1.
The overall incidence of AF in the whole study sample
as 24.4% (39 of 160 patients). Postoperative AF occurred
n 15.2% (12 of 79) of the patients in the PUFA group
ompared with 33.3% (27 of 81) of those in the control
roup (OR 0.35; 95% confidence interval [CI] 0.16 to 0.76;
 0.013). The consequent number of patients needed to
reat was 5.51 (95% CI 3.43 to 20.40).
The Kaplan-Meier actuarial estimates of occurrence of
ostoperative AF in the study group are shown in Figure 1.
Atrial fibrillation occurred a mean of 3.2  1.1 days after
urgery in patients assigned to PUFAs and 3.4  1.3 days
fter surgery in controls (p  0.645); AF was diagnosed
uring continuous electocardiographic monitoring in the
ntensive or intermediate care units in 11 of 12 (91.6%)
atients in the PUFA group and in 25 of 27 (92.5%)
atients in the control group (p 0.919 by chi-square). The
emaining cases of AF (one in the PUFA group and two in
he control group) were detected by electrocardiography
fter the occurrence of symptoms. The mean duration of AF
as of 15.5 15.8 h in patients assigned to PUFA and 23.9
Table 1. Patients’ Clinical and Surgical Data
Con
Age, yrs
Male gender
Systemic hypertension
Diabetes mellitus
COP disease
Chronic renal failure
NYHA functional class
Previous myocardial infarction
Perioperative medication
Beta-blockers
Calcium channel blockers
Nitrates
Diuretics
ACE inhibitors
Angiotensin receptor blockers
Statins
Acitelsalicilic acid
Ejection fraction, %
Left atrial AP dimension, mm
Cardiopulmonary bypass time, min
Aorta cross-clamp time, min
Sapheneous vein grafts, no./patient
Internal thoracic artery grafts, no./patient
Off pump CABG
*All comparisons for categorical variables were performed by
AP  anteroposterior; ACE  angiotensin-converting enzyme
obstructive pulmonary; NYHA  New York Heart Association; P15.3 h in controls (p  0.125). Symptoms attributable to
F were reported by 10 of 12 patients (83.3%) in the PUFA
roup and by 24 of 27 (88.8%) controls (p  0.634 by
hi-square); AF was initially treated by amiodarone in 9 of
2 patients assigned to PUFA and in 22 of 27 controls (p
.643 by chi-square). Spontaneous conversion to sinus
hythm without any intervention occurred in two patients
eceiving PUFAs and in three controls (p 0.631 by Fisher
xact test). Electrical cardioversion was performed on one
atient in the PUFA group and in two controls (p  0.920
y Fisher exact test).
Two of 12 (16.6%) patients in the PUFA group had more
han one episode of AF during hospitalization (two episodes
nd three episodes, respectively), while 5 of 27 (18.5%)
atients in the control group had more than one episode of
F (three patients had two episodes and two patients had
hree episodes) (p  0.889 by Fisher exact test).
Four patients (two from the PUFA group and two
ontrols) presented to the outpatient department owing to
cute symptoms (dyspnea, fatigue, chest discomfort) after
ischarge and before the planned follow-up visit. In all of
hese cases, sinus rhythm was present.
Patients had a follow-up visit in the outpatient depart-
ent 28  8 days after surgery, and sinus rhythm was
resent in each patient.
In the multivariate analysis, two variables were noted to
e significant independent predictors of postoperative AF:
ge (OR 1.08; 95% CI 1.01 to 1.15; p  0.022) and the use
f PUFAs (OR 0.32; 95% CI 0.10 to 0.98; p  0.013).
(n  81) PUFAs (n  79) p Value*
9.1 66.2  8.0 0.34
4%) 68 (86%) 0.88
1.5%) 62 (78.5%) 0.78
2.1%) 26 (32.9%) 1.0
6%) 13 (16.4%) 0.94
.6%) 8 (10.1%) 0.74
0.8 1.7  0.8 0.43
3.1%) 41 (51.9%) 1.0
6.8%) 46 (58.2%) 0.98
0.9%) 22 (27.8%) 0.67
5.3%) 60 (74.1%) 0.92
2.1%) 24 (30.4%) 0.81
9.3%) 46 (58.2%) 0.89
8.5%) 18 (22.8%) 0.50
4.3%) 47 (59.4%) 0.50
4.3%) 47 (59.4%) 0.50
11.4 56.3  12.1 0.56
5.2 39.7  5.1 0.90
26.3 101.  27.4 0.32
22.1 66.6  23.1 0.85
1.1 2.4  1.2 0.58
0.5 1.0  0.3 0.12
2.3%) 9 (11.4%) 0.95
quare analysis.trols
64.9 
68 (8
66 (8
26 (3
13 (1
7 (8
1.6 
43 (5
46 (5
25 (3
61 (7
26 (3
48 (5
15 (1
44 (5
44 (5
55.3 
39.7 
96.7 
65.9 
2.3 
0.9 
10 (1
chi-s
; CABG  coronary artery bypass surgery; COP  chronic
UFAs  polyunsaturated fatty acids.
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N-3 Fatty Acids and Postoperative AF May 17, 2005:1723–8nfluence of beta-blocker therapy. The use of beta-
lockers did not influence the prevalence of AF in either
tudy group. Of 79 patients on PUFAs, 46 (56.8%) were on
eta-blockers. Of these, seven (15.2%) developed AF,
hereas five (15.1%) of the patients not taking beta-
lockers had AF. In the control group, the prevalence of AF
as 34.8% (16 of 46 patients) among the patients on
eta-blockers and 31.4% (11 of 35 patients) among those
ot receiving beta-blockers.
n-hospital morbidity and mortality. One patient in the
UFA group developed allergic skin rash on the first day of
rug administration, and PUFAs were discontinued. Non-
atal postoperative complications occurred in seven (8.6%)
atients of the control group (two acute renal failure, one
neumonia, two pneumotorax, one pulmonary edema, one
astrointestinal bleeding) and in five (6.3%) patients of the
UFA group (one acute renal failure, one implantation of
ermanent pacemaker, one pneumotorax, one adult respi-
atory distress syndrome, one redo for pericardial bleeding)
p  0.8 by Fisher exact test). There were two deaths in the
ontrol group (2.5%) and one death in the PUFA group
1.3%) (p  1.0 by Fisher exact test).
ength of hospital stay. Patients assigned to PUFAs had
shorter length of hospital stay as compared with controls
7.3  2.1 days, 95% CI for mean 6.8 to 7.7 vs. 8.2  2.6
ays, 95% CI for mean 7.6 to 8.7, p  0.017). When
onsidering the overall population, patients with AF had a
onger length of hospital stay than those without AF (9.4 
igure 1. The Kaplan-Meier actuarial estimates of occurrence of postope
cids..0 days, 95% CI for mean 8.4 to 10.3 vs. 7.2  1.9 days, a5% CI for mean 6.8 to 7.5, p  0.0004). In the PUFA
roup, the mean length of stay was 9.6  3.1 days (95% CI
or mean 7.5 to 11.5) for patients with AF and 6.9  1.6
ays (95% CI for mean 6.4 to 7.2) for those without AF (p
0.01). In the control group, patients with AF also had a
onger hospital stay as compared with those without AF (9.3
2.9 days, 95% CI for mean 8.1 to 10.4 vs. 7.6  2.2 days,
5% CI for mean 7.0 to 8.2, p  0.01).
ISCUSSION
ain findings. In this trial, the use of PUFAs during
ospitalization in patients undergoing CABG significantly
educed the incidence of postoperative AF (18.1% absolute
isk reduction, 54.4% relative risk reduction) and was
ssociated with a shorter hospital stay. Except for a single
ase of allergic response, no significant adverse reactions
ere observed.
revious studies. The issue of prevention of postoperative
F in cardiac surgery was addressed by a number of studies.
everal agents, including digitalis, calcium antagonists, pro-
ainamide, quinidine, and propafenone did not show any
eneficial effect (1,26–29). A meta-analysis, which included
2 trials conducted before 2001, compared several agents
beta-blockers, sotalol, and amiodarone) with placebo (2).
eta-blockers (27 trials, 3,840 patients) were found to
educe the incidence of AF from 33% to 19%, while sotalol
8 trials, 1,294 patients) reduced the occurrence of the
atrial fibrillation in the study group. PUFA  n-3 polyunsaturated fattyrrhythmia from 37% to 17%. In four comparative trials
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May 17, 2005:1723–8 N-3 Fatty Acids and Postoperative AF900 patients), sotalol scored better than conventional beta-
lockers (12% incidence of AF vs. 22%). However, all trials
mploying beta-blockers or sotalol excluded patients with
radycardia and obstructive lung disease. Moreover, most
tudies excluded patients with depressed left ventricular
unction or heart failure. Amiodarone was evaluated in nine
rials, including 1,384 patients, and reduced the occurrence
f AF from 37% to 22.5%. Also, a recent trial compared
miodarone plus metoprolol, metoprolol alone, and sotalol
ith placebo (29). Only the combination therapy and sotalol
educed the relative risk of postoperative AF, respectively,
y 45% and 41%.
In this study, the incidence of AF in the placebo group
as of 33%, which is similar to the mean incidence of AF
eported in the literature. In our study, PUFAs determined
reduction of the relative risk of postoperative AF of 54.4%,
hereby favorably comparing with the 43% reduction ob-
ained by beta-blockers, the 54% reduction observed with
otalol, and the 39% reduction associated with amiodarone
se. In addition, differently from beta-blockers and sotalol,
hich can be associated with cases of significant bradycardia
nd persistent hypotension (29), PUFAs showed a particu-
arly low incidence of adverse effects, and could be used in all
atients, including those with respiratory insufficiency or
eart failure.
he antiarrhythmic effect of PUFAs. Back in 1985, a
tudy first reported that polyunsaturated alpha-linoleic acid
owered the arrhythmia threshold of the isolated rabbit
eart (16). Several reports followed such initial findings and
emonstrated that PUFAs may exert a protective effect
gainst fatal ventricular arrhythmias in animal models after
xperimental coronary ligation (18,19).
The electrophysiological basis of such effect has been
larified in other studies, showing at least three possible
odes of action for the PUFAs on the myocyte (6,7,17): a
light hyperpolarization of the resting membrane potential,
n increase of the current necessary to elicit an action
otential, and an increase of the phase 4 refractory period.
hese effects were found to be related to an inhibition of the
odium current INa (12), of the calcium current ICaL (15),
nd, possibly, of the potassium currents IK and Ito (6). These
ffects account for an increased electrical stability that may
esult in a significant protection against fibrillation, which
as been actually demonstrated in vitro (17).
Epidemiological surveys suggest that fish oil consumption
ay reduce the risk of fatal ventricular arrhythmias, consis-
ently supporting an antiarrhythmic effect of PUFAs
9,10,21–25).
The main hypothesis of our study was that the antiar-
hythmic properties of PUFAs could also extend to the
trial myocardium, thereby protecting against the occur-
ence of AF. Actually, even if a previous study showed that
UFAs may reduce the asynchronous contractile activity of
trial myocytes (24), to date, the effects of PUFAs on
upraventricular arrhythmias have not been fully investi-
ated. In fact, our findings represent the first direct evidence rhat PUFA supplementation may, indeed, be effective in
reventing AF. Furthermore, our findings are in keeping
ith a recent study in which the consumption of tuna, and
ther broiled or baked fish, was associated with a 30% lower
ncidence of AF in a 12-year follow-up (25). Interestingly,
nly the consumption of fish inducing higher concentra-
ions of long chain n-3 fatty acids was associated with an
ntiarrhythmic effect, while the intake of fried fish or fish
andwiches did not induce higher plasma levels of PUFAs
nd did not show any protective effect against AF.
he anti-inflammatory hypothesis. A possible role of
nflammation in the pathophysiology of postoperative
F has been repeatedly suggested (30,31), and the anti-
nflammatory activity of PUFAs is now well-documented
32–35). There are several clinical studies reporting that
UFAs have beneficial effects in acute and chronic inflamma-
ory diseases (32–34). Furthermore, it has been observed that
PA can act as a competitive inhibitor of arachidonic acid
onversion to prostaglandin E2 and leukotriene B4, while a
ecreased synthesis of both of these eicosanoids has been
bserved after inclusion of fish oil in the diet (32,33). The
nclusion of DHA in the diet may also result in decreased
ynthesis of leukotriene B4 (32,33). As to the proinflammatory
ytokines, it has been shown that dietary supplementation with
ncapsulated fish oil may result in a decreased monocyte
ynthesis of tumor necrosis factor-alpha and interleukin 1 in
umans (35). Consequently, we can hypothesize that an
nti-inflammatory action of PUFAs could play a role in the
revention of AF after cardiothoracic surgery.
tudy limitations. The present study was not formally
linded; we acknowledge this as a limitation. However, this
ethodological limit should not have influenced the main
esults of the trial. In fact, two independent cardiologists,
ho were blinded to treatment allocation, formally adjudi-
ated the primary end point of the study and computed the
ospital length of stay on the basis of clinical records and
lectrocardiographic tracings after discharge. This approach
omehow resembles that used in other trials, which em-
loyed a blinded end point committee (36).
Patients undergoing valvular surgery and patients with
revious AF were excluded. Both valvular surgery and
istory of AF are factors that increase the risk of postoper-
tive AF (1). Consequently, patients with these conditions
ere preliminarily excluded in order to avoid any possible
onfounding factor. The results of the present study are,
herefore, applicable only to patients with no history of AF
ndergoing isolated CABG.
The patients in the PUFA group were hospitalized for
ignificantly fewer days than those in the control group.
onsequently, patients assigned to PUFA may possibly
ave had asymptomatic episodes of AF after discharge that
ere not identified. We also acknowledge this point as a
otential limitation of the study.
onclusions. n-3 Polyunsaturated fatty acid supplementa-
ions in patients undergoing isolated CABG significantly
educes the occurrence of postoperative AF, with an effect
t
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N-3 Fatty Acids and Postoperative AF May 17, 2005:1723–8hat is similar to that obtained with beta-blockers, sotalol,
nd amiodarone. In addition, PUFA supplementation is
afe and can be administered to all patients undergoing
ABG without the exclusion of any patient.
This is the first direct evidence of an atrial antiarrhythmic
ffect of PUFAs and may pave the way to other studies
imed at defining any possible atrial antifibrillatory effect of
UFAs in other clinical conditions.
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